Search

Your search keyword '"Anna Luisa Di Stefano"' showing total 90 results

Search Constraints

Start Over You searched for: Author "Anna Luisa Di Stefano" Remove constraint Author: "Anna Luisa Di Stefano"
90 results on '"Anna Luisa Di Stefano"'

Search Results

1. Targeting Mitochondria in Glioma: New Hopes for a Cure

2. Exploring Regorafenib Responsiveness and Uncovering Molecular Mechanisms in Recurrent Glioblastoma Tumors through Longitudinal In Vitro Sampling

3. Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan.

4. Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.

6. Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study

7. In Vivo 2-Hydroxyglutarate Monitoring With Edited MR Spectroscopy for the Follow-up ofIDH-Mutant Diffuse Gliomas

8. Innovative Approach to Isolate and Characterize Glioblastoma Circulating Tumor Cells and Correlation with Tumor Mutational Status

10. Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials

11. Hybrid [18F]-F-DOPA PET/MRI Interpretation Criteria and Scores for Glioma Follow-up After Radiotherapy

12. Supplementary Figure 4 from Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma

13. Supplementary Figure 3 from Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma

14. Supplementary Figure 2 from Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma

15. Supplementary Figure Legends from Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma

16. Supplementary Table 1 from Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma

17. Supplementary Figure 6 from Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma

18. Data from Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma

19. Supplementary Figure 1 from Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma

20. Supplementary Figure 5 from Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma

21. Incidence and Characteristics of Pseudoprogression in IDH-mutant High-Grade Gliomas: A POLA Network Study

22. Integrative multi-omics networks identify PKCδ and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy

23. Characteristics, Patterns of Care and Predictive Geriatric Factors in Elderly Patients Treated for High-Grade IDH-Mutant Gliomas: A French POLA Network Study

25. Sustained Tumor Control With MAPK Inhibition in BRAF V600–Mutant Adult Glial and Glioneuronal Tumors

26. Multimodal management of surgery- and radiation-refractory meningiomas: an analysis of the French national tumor board meeting on meningiomas cohort

27. In Vivo 2-Hydroxyglutarate Monitoring With Edited MR Spectroscopy for the Follow-up of

28. BIOM-35. A NEW PRECISION-MEDICINE APPROACH TO PREDICT TUMOR TREATMENT RESPONSE IDENTIFIES IN GLIOBLASTOMA A 17 GENE SIGNATURE PROGNOSTIC OF TMZ RESPONSE AND SURVIVAL WITH ROBUST PREDICTIVE VALUE

29. EXTH-21. DEVELOPMENT OF THERAPEUTIC STRATEGIES BY PATHWAY-BASED MULTI-OMICS APPROACH AND MASTER KINASE ANALYSIS IN GLIOBLASTOMA MULTIFORME

30. Hybrid [

31. The French glioblastoma biobank (FGB): a national clinicobiological database

32. Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy

33. Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities

34. Descriptive and retrospective analysis of diffuse glioma patients with symptomatic SARS-CoV2 infection during the first wave of the pandemic

35. Sustained Tumor Control With MAPK Inhibition in

36. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

37. IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification

38. Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma

39. Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions

40. Correction to: The French glioblastoma biobank (FGB): a national clinicobiological database

41. Innovating Strategies and Tailored Approaches in Neuro-Oncology

42. NCOG-09. PREDICTIVE GERIATRIC FACTORS IN ELDERLY PATIENTS TREATED FOR IDH-MUTANT HIGH-GRADE GLIOMAS: A FRENCH POLA NETWORK STUDY

43. Potentiel clinique de la spectroscopie MEGA-PRESS dans les gliomes diffus IDH mutés

44. CNS inflammatory disorder after concurrent radiotherapy-temozolomide and nivolumab in a glioblastoma patient

45. EGFR gene amplification in monocentric and multicentric glioblastoma

46. Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: the platum trial

47. Manifestations cliniques et facteurs pronostiques de la COVID-19 chez les patients souffrant de gliome diffus

48. The clinical use of IDH1 and IDH2 mutations in gliomas

49. Current and future tools for determination and monitoring of isocitrate dehydrogenase status in gliomas

50. Vemurafenib and cobimetinib overcome resistance to vemurafenib in BRAF-mutant ganglioglioma

Catalog

Books, media, physical & digital resources